MP11: Prostate Cancer: Advanced (including Drug Therapy) I

Friday, April 28, 2023

9:30 AM – 11:30 AM CST

Location: S504

CE: 1

Poster Session Moderator(s)

Nathan Lawrentschuk, PHD,MBBS

Professor
University of Melbourne
Todd Morgan, MD

University of Michigan

Presentations:

9:30 AM – 11:30 AM CST

MP11-01: Prescription Patterns of Systemic Therapy in the Management of Metastatic Castration-Sensitive Prostate Cancer
Poster Presenter: Joseph B. Black, MD, PHD
9:30 AM – 11:30 AM CST

MP11-02: Treatment trends in patients with de novo metastatic prostate cancer in the era of upfront combination therapy
Poster Presenter: Sasaki Daichi
9:30 AM – 11:30 AM CST

MP11-03: Preferences for Key Attributes of Clinically Available Androgen Deprivation Therapies Among Men with Prostate Cancer
Poster Presenter: Sean P. Collins
9:30 AM – 11:30 AM CST

MP11-04: Androgen-deprivation therapy and the risk of newly developed neovascular age-related macular degeneration in patients with prostate cancer: a nested case-control study
Poster Presenter: Junseok Kim, MD
9:30 AM – 11:30 AM CST

MP11-05: Tumor heterogeneity and drug sensitivity modelled in primary prostate cancer organoids
Poster Presenter: George Niklaus Thalmann, MD (he/him/his) – University of Berne
9:30 AM – 11:30 AM CST

MP11-06: The prognostic role of 68Ga-PSMA PET/CT and the impact of Metastasis-Directed Therapy on cancer progression in men with biochemical recurrence from prostate cancer. Results from a large, single Institution series.
Poster Presenter: Daniele Robesti, MD – Universti� Vita Salute San Raffaele
9:30 AM – 11:30 AM CST

MP11-07: Radioligand Therapy with ¹⁷⁷Lu-PSMA-I&T in Patients with Metastatic Castration-Resistant Prostate Cancer: Oncological Outcomes and Toxicity Profile
Poster Presenter: Baris Esen
9:30 AM – 11:30 AM CST

MP11-08: Exploring the Effect of Metastasis Directed Therapy on Progression Patterns of Patients with Positive 68Ga-PSMA PET/CT and Biochemical Recurrence from Prostate Cancer.
Poster Presenter: Antony Angelo Pellegrino, MD
9:30 AM – 11:30 AM CST

MP11-09: Second line PSMA-targeted salvage treatment in patients with miN1/M1a-b oligorecurrent PCa
Poster Presenter: Eleonora Balestrazzi, MD
9:30 AM – 11:30 AM CST

MP11-10: ISOLATED IN-FIELD RECURRENCE FOLLOWING RADICAL PROSTATECTOMY AND RADIATION
Poster Presenter: Cameron Britton, MD, BS – Mayo Clinic
9:30 AM – 11:30 AM CST

MP11-11: Tailoring the optimal use of Androgen-Deprivation Therapy concomitant to post-operative Radiotherapy among men with pN1 prostate cancer. Long-term results of a large, single Institution series.
Poster Presenter: Elio Mazzone
9:30 AM – 11:30 AM CST

MP11-12: Development of a risk model for time to second progression in patients with high-risk metastatic castration-sensitive prostate cancer treated with abiraterone acetate and androgen deprivation therapy
Poster Presenter: Shintaro Narita, MD, PhD
9:30 AM – 11:30 AM CST

MP11-13: Clinical fracture incidence in metastatic hormone-sensitive prostate cancer (mHSPC) and risk-reduction following addition of zoledronic acid to androgen deprivation therapy (ADT) with or without docetaxel (Doc): long-term results from 2 phase 3 trials from the STAMPEDE platform protocol
Poster Presenter: Craig Jones, FRCS,MBBS (he/him/his)
9:30 AM – 11:30 AM CST

MP11-14: Treatment duration and long-term safety and tolerability with darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC): ARAMIS Rollover Study
Poster Presenter: Neal D. Shore, MD (he/him/his)
9:30 AM – 11:30 AM CST

MP11-15: The effect of a reduced dose of apalutamide on skin-related adverse events in advanced prostate cancer: A multicenter retrospective study
Poster Presenter: Kyo Togashi, MD (he/him/his) – Graduate School of Medicine, Hirosaki Univers
9:30 AM – 11:30 AM CST

MP11-16: Prostate-specific antigen analyses in PROpel: abiraterone and olaparib versus abiraterone and placebo as first-line therapy for metastatic castration-resistant prostate cancer
Podium Presenter: Fred Saad, MD,FRCSC – University of Montreal Hospital Center
9:30 AM – 11:30 AM CST

MP11-17: Signet ring cells on prostate biopsy in the setting of primary acinar adenocarcinoma
Poster Presenter: Daniel Nemirovsky